The United States is signaling it may open a formal trade investigation into Switzerland’s pharmaceutical industry, a move that could reshape one of the most consequential economic relationships in global healthcare.
For context, pharmaceuticals make up nearly half of all Swiss exports to the US, totaling roughly $35.5 billion in 2024. That’s not a minor trade lane. That’s the backbone of Switzerland’s economic ties with its largest trading partner.
The tariff saga so far
US tariffs on Swiss goods peaked at 39% in August 2025, imposed under Section 232, the same national security provision that previously targeted steel and aluminum imports from various countries.
Pharmaceuticals were initially carved out of the broader tariff action. But the threat of inclusion under Section 232 probes loomed large enough to send Swiss industry executives scrambling for contingency plans.
